Pfizer defends steep price increases in the USA

8 June 2017
pfizer-logo-big

New York, USA-based pharmaceutical giant Pfizer (NYSE: PFE) has defended its decision to raise the price of around 100 drugs in the US market by up to 20% in 2017.

In a statement, the company said: “Pfizer has always priced responsibly and believes that innovative medicines are one of the most valuable and cost effective segments of healthcare spend.”

When Allergan (NYSE: AGN) chief executive Brent Saunders vowed late last year to limit annual price increases to single digits, it seemed to mark a change in mood over US pricing.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical